BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 12675312)

  • 1. Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates.
    Patel M; McCully C; Godwin K; Balis FM
    J Neurooncol; 2003 Feb; 61(3):203-7. PubMed ID: 12675312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients.
    Ostermann S; Csajka C; Buclin T; Leyvraz S; Lejeune F; Decosterd LA; Stupp R
    Clin Cancer Res; 2004 Jun; 10(11):3728-36. PubMed ID: 15173079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-performance liquid chromatographic determination and stability of 5-(3-methyltriazen-1-yl)-imidazo-4-carboximide, the biologically active product of the antitumor agent temozolomide, in human plasma.
    Kim HK; Lin CC; Parker D; Veals J; Lim J; Likhari P; Statkevich P; Marco A; Nomeir AA
    J Chromatogr B Biomed Sci Appl; 1997 Dec; 703(1-2):225-33. PubMed ID: 9448080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma and cerebrospinal fluid pharmacokinetics of select chemotherapeutic agents following intranasal delivery in a non-human primate model.
    League-Pascual JC; Lester-McCully CM; Shandilya S; Ronner L; Rodgers L; Cruz R; Peer CJ; Figg WD; Warren KE
    J Neurooncol; 2017 May; 132(3):401-407. PubMed ID: 28290002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of 3-methyl-(triazen-1-yl)imidazole-4-carboximide following administration of temozolomide to patients with advanced cancer.
    Reid JM; Stevens DC; Rubin J; Ames MM
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2393-8. PubMed ID: 9815639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial of temozolomide using an extended continuous oral schedule.
    Brock CS; Newlands ES; Wedge SR; Bower M; Evans H; Colquhoun I; Roddie M; Glaser M; Brampton MH; Rustin GJ
    Cancer Res; 1998 Oct; 58(19):4363-7. PubMed ID: 9766665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates.
    Blaney SM; Cole DE; Balis FM; Godwin K; Poplack DG
    Cancer Res; 1993 Feb; 53(4):725-7. PubMed ID: 8428353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The plasma and cerebrospinal fluid pharmacokinetics of sorafenib after intravenous administration in non-human primates.
    Kim A; McCully C; Cruz R; Cole DE; Fox E; Balis FM; Widemann BC
    Invest New Drugs; 2012 Apr; 30(2):524-8. PubMed ID: 21072558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration.
    Marzolini C; Decosterd LA; Shen F; Gander M; Leyvraz S; Bauer J; Buclin T; Biollaz J; Lejeune F
    Cancer Chemother Pharmacol; 1998; 42(6):433-40. PubMed ID: 9788568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting human tumor drug concentrations from a preclinical pharmacokinetic model of temozolomide brain disposition.
    Zhou Q; Guo P; Kruh GD; Vicini P; Wang X; Gallo JM
    Clin Cancer Res; 2007 Jul; 13(14):4271-9. PubMed ID: 17634557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disposition and pharmacokinetics of temozolomide in rat.
    Reyderman L; Statkevich P; Thonoor CM; Patrick J; Batra VK; Wirth M
    Xenobiotica; 2004 May; 34(5):487-500. PubMed ID: 15370964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic study of temozolomide on a daily-for-5-days schedule in Japanese patients with relapsed malignant gliomas: first study in Asians.
    Aoki T; Nishikawa R; Mizutani T; Nojima K; Mishima K; Adachi J; Matsutani M
    Int J Clin Oncol; 2007 Oct; 12(5):341-9. PubMed ID: 17929115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of gastric pH on the relative oral bioavailability and pharmacokinetics of temozolomide.
    Beale P; Judson I; Moore S; Statkevich P; Marco A; Cutler DL; Reidenberg P; Brada M
    Cancer Chemother Pharmacol; 1999; 44(5):389-94. PubMed ID: 10501912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An LC/MS/MS method for the quantitation of MTIC (5-(3-N-methyltriazen-1-yl)-imidazole-4-carboxamide), a bioconversion product of temozolomide, in rat and dog plasma.
    Chowdhury SK; Laudicina D; Blumenkrantz N; Wirth M; Alton KB
    J Pharm Biomed Anal; 1999 Apr; 19(5):659-68. PubMed ID: 10698531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of regadenoson-induced transient disruption of the blood-brain barrier on temozolomide delivery to normal rat brain.
    Jackson S; Anders NM; Mangraviti A; Wanjiku TM; Sankey EW; Liu A; Brem H; Tyler B; Rudek MA; Grossman SA
    J Neurooncol; 2016 Feb; 126(3):433-9. PubMed ID: 26626489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The plasma pharmacokinetics and cerebrospinal fluid penetration of the thymidylate synthase inhibitor raltitrexed (Tomudex) in a nonhuman primate model.
    Widemann BC; Balis FM; Godwin KS; McCully C; Adamson PC
    Cancer Chemother Pharmacol; 1999; 44(6):439-43. PubMed ID: 10550563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma and cerebrospinal fluid pharmacokinetics of SU5416 after intravenous administration in nonhuman primates.
    Renbarger J; Aleksic A; McGuffey L; Dauser R; Berg S; Blaney S
    Cancer Chemother Pharmacol; 2004 Jan; 53(1):39-42. PubMed ID: 14551735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma and cerebrospinal fluid pharmacokinetics of the histone deacetylase inhibitor, belinostat (PXD101), in non-human primates.
    Warren KE; McCully C; Dvinge H; Tjørnelund J; Sehested M; Lichenstein HS; Balis FM
    Cancer Chemother Pharmacol; 2008 Aug; 62(3):433-7. PubMed ID: 17960383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and cerebrospinal fluid penetration of CI-994 (N-acetyldinaline) in the nonhuman primate.
    Riva L; Blaney SM; Dauser R; Nuchtern JG; Durfee J; McGuffey L; Berg SL
    Clin Cancer Res; 2000 Mar; 6(3):994-7. PubMed ID: 10741726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I trial of 1,3-bis(2-chloroethyl)-1-nitrosourea plus temozolomide: a North American Brain Tumor Consortium study.
    Schold SC; Kuhn JG; Chang SM; Bosik ME; Robins HI; Mehta MP; Spence AM; Fulton D; Fink KL; Prados MD
    Neuro Oncol; 2000 Jan; 2(1):34-9. PubMed ID: 11302252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.